Clinuvel Pharmaceuticals Expects US Shutdown to Impact ADR Program Upgrade Deadlines

MT Newswires Live
Nov 03, 2025

Clinuvel Pharmaceuticals (ASX:CUV) said it expects the ongoing US Federal Government shutdown to impact the deadline for the upgrade of its American Depositary Receipt Level program from level one to level two, according to a Monday filing with the Australian bourse.

The US administration expects a longer turnaround time for the review and approval of the registration statements filed with the US Securities and Exchange Commission, the filing said.

The review and approval are expected to be completed only after the shutdown is resolved, the filing added.

Shares of the company fell nearly 1% in recent Monday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10